Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients

de, Lafuente Yanina; García, Mónica Cristina; Jiminez-Kairuz, Alvaro

Abstract

Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients

Author(s): de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro

Issue: Jul/Aug 2019 - Volume 23, Number 4

View All Articles in Issue

Page(s): 324-331

Download in electronic PDF format for $75

Abstract

Indomethacin is used for off-label prescription for the treatment of patent ductus arteriosus in premature infants. In Argentina, indomethacin is only available as a suppository, dermic cream, injectable ampules, and delayed-release capsules. Aiming to improve pediatric treatment and minimize the risk associated with improper dosage, this work focused on the development of an extemporaneous 0.2% indomethacin oral suspension, starting from the commercially injectable formulation. Two 150-mL batches of suspension were prepared using Generally Recognized as Safe excipients. The suspensions were stored for 17 days at room temperature. Physical stability, morphological analysis of suspended particles, sedimentation volume, easy re-suspension, and dynamic viscosity were studied. The indomethacin content, dissolution studies, and microbiological attributes of nonsterile pharmaceutical products were also evaluated. After 17 days of storage, the suspension was easily re-dispersed after 15 seconds of the hand-shaking technique. There were no detectable changes in color, odor, and/or flavor. The suspension showed minimal changes in pH, viscosity, shape, and mean size of the suspended indomethacin particles. The content uniformity and drug dissolution remained within the acceptable range during storage. This oral liquid suspension is an interesting alternative to be prepared by hospital pharmacy services for optimizing the pediatric treatment of patent ductus arteriosus.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page View/Buy	Title/Author (Click for Abstract / Details / Purchase)
Jul/Aug 2019 Pg. 324-331	Extemporaneous Indomethacin Oral Suspension Prepared from Injectable Ampules for Therapy in Premature Infants and Pediatric Patients Author(s): de Lafuente Yanina, García Mónica Cristina, Jiminez-Kairuz Alvaro
Sep/Oct 2013 Pg. 419	Indomethacin 1-mg/mL Injection Author(s): Allen Loyd V Jr
Mar/Apr 2004 Pg. 101-105	Pluronic Lecithin Organogel for Local Delivery of Anti-Inflammatory Drugs Author(s): Frankum James, Ramsay Dale, Das Nandita G, Das Sudip K
Jul/Aug 2017 Pg. 322-329	Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox) Author(s): Ip Kendice, Carvalho Maria, Shan Ashley, Banov Daniel
Jan/Feb 2001 Pg. 9-12	Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients Author(s): Schotik Debora
Jan/Feb 2001 Pg. 6-8	Pediatric Compounding: Coloring Outside the Lines Author(s): Preckshot John
May/Jun 2003 Pg. 233-239	Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets Author(s): Kaila Nitin, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
Jan/Feb 2023 Pg. 72-77	Physicochemical Stability of the Extemporaneous Ibuprofen Oral Suspension in "Wagner" Base Author(s): Spennacchio Antonio, Lopedota Angela, la Forgia Flavia, Fontana Sergio, Franco Massimo, Denora Nunzio
Nov/Dec 1999 Pg. 496-500	Enhancement of Skin Penetration of Nonsteroidal Anti-Inflammatory Drugs from Extemporaneously Compounded Topical-Gel Formulations Author(s): Goodwin Donald A, Fuhram L Clifton
Nov/Dec 2006 Pg. 458	Indomethacin 2-mg/mL Oral Liquid Author(s): Allen Loyd V Jr
Jul/Aug 2022 Pg. 325-326	Indomethacin 1% Topical Gel Author(s): Allen Loyd V Jr
Jul/Aug 1999 Pg. 274-276	Extemporaneous Formulations in Pediatric Patients Author(s): Nahata Milap C
Jan/Feb 2016 Pg. 6-10	Extemporaneous Compounding of Oral Acitretin Suspension for Pediatric Patient with Generalized Pustular Psoriasis Author(s): Choo Winnie
Mar/Apr 1997 Pg. 84-86	Compounding for the Pediatric Patient Author(s): Allen Loyd V Jr
Sep/Oct 2003 Pg. 389-393	Formulation and Accelerated Stability Studies for an Extemporaneous Suspension of Amiodarone Hydrochloride Author(s): Alexander Kenneth S, Thyangarajapuram N
Nov/Dec 2008 Pg. 543	Indomethacin 2% in Pluronic Lecithin Organogel Author(s): Allen Loyd V Jr
Nov/Dec 2008 Pg. 541	Cyclobenzaprine Hydrochloride 1%, Dextromethorphan Hydrobromide 10%, Guaifenesin 10%, and Indomethacin 20% Penetrating Gel Author(s): Allen Loyd V Jr
Mar/Apr 2024 Pg. 151-155	Physical-chemical Stability of the Extemporaneous Paracetamol Oral Suspension in Puccini Base Author(s): Lacassia Chiara, Spennacchio Antonio, Lopedota Angela Assunta, la Forgia Flavia Maria, Fontana Sergio, Denora Nunzio, Lopalco Antonio
Jan/Feb 2007 Pg. 26-27	Case Report: Cocktail Dosing in a Premature Infant with a History of Cholestasis Author(s): Fields Shannon W
May/Jun 2016 Pg. 230	Indomethacin Gel Author(s): Allen Loyd V Jr